The Transcatheter Cardiovascular Therapeutics (TCT) unveiled its lineup of clinical trials to be presented at its 2013 scientific sessions. The conference, TCT’s 25th, is scheduled to take place Oct. 28-Nov. 1 in San Francisco.

Below is the schedule:

Oct. 29

Late-breaking clinical trials

• SAFE-PCI: A prospective, registry-based randomized trial of radial vs. femoral vascular access in women undergoing diagnostic cardiac catheterization and PCI
• COREVALVE EXTREME RISK: A prospective registry study of transcatheter aortic valve replacement with a self-expanding transcatheter heart valve in patients with severe aortic stenosis
• SORT-OUT VI: A prospective, randomized “all-comers” trial of biodegradable polymer-coated biolimus-eluting stents vs. biocompatible polymer-coated zotarolimus-eluting coronary stents

Oct. 30

Late-breaking clinical trials

• EUROMAX: A prospective, randomized trial of ambulance initiation of bivalirudin vs. heparin ± glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI
• NORDIC-BALTIC BIFURCATION IV: A prospective, randomized trial of a two-stent strategy vs. a provisional stent strategy in true coronary bifurcation lesions
• TRYTON: A prospective, randomized trial of a dedicated sidebranch stent vs. a provisional stent strategy in true coronary bifurcation lesions

First report investigations

• LEVANT 2: A prospective, randomized trial of a paclitaxel-coated balloon vs. standard balloon angioplasty in diseased femoropopliteal arteries
• RIBS V: A prospective, randomized trial of paclitaxel-coated balloon angioplasty vs. everolimus-eluting stents in bare metal in-stent restenosis
• SMART-CASE: A prospective, randomized trial of conservative revascularization vs. aggressive revascularization in patients with intermediate lesions undergoing PCI with angiographic guidance alone
• HeartFlowNXT: A prospective, registry evaluation of noninvasive FFRCT vs. invasive FFR
• ADVISE II: A prospective, registry evaluation of iFR vs. FFR
• CHILL-MI: A prospective, randomized trial of therapeutic hypothermia in patients with acute myocardial infarction undergoing primary PCI

Oct. 31

Late-breaking clinical trials

• OPTIMIZE: A prospective, randomized trial of three months vs. 12 months of dual antiplatelet therapy After PCI
• ARCTIC-INTERRUPTION: A prospective, randomized trial of two years vs. one year of dual antiplatelet therapy After PCI
• DUTCH PEERS (TWENTE II): A prospective, randomized “all-comers” trial of zotarolimus-eluting stents vs. everolimus-eluting coronary stents

First report investigations

• REPRISE II: A prospective registry study of transcatheter aortic valve replacement with a repositionable transcatheter heart valve in patients with severe sortic stenosis
• FREEDOM: A prospective, randomized trial of first-generation DES vs.  CABG in insulin and non-insulin treated diabetic patients
• HYBRID: A prospective, randomized trial of hybrid coronary revascularization vs. standard surgical revascularization in multivessel disease
• TRANSLATE-POPS: A prospective, cluster-randomized trial of routine platelet function testing in patients undergoing PCI
• GIANT: A prospective registry study of CYP2C19 genetic profiling for thienopyridine management after primary PCI in acute myocardial infarction
• TATORT-NSTEMI: A prospective, randomized trial of thrombus aspiration in thrombus-containing culprit lesions in Non-ST-Segment Elevation Myocardial Infarction